Skip to main content
Contact Us
Subscribe
E-Edition
56°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Revance Therapeutics
(NQ:
RVNC
)
4.900
-0.040 (-0.81%)
Streaming Delayed Price
Updated: 11:52 AM EDT, Mar 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Revance Therapeutics
< Previous
1
2
3
4
5
6
7
8
9
Next >
Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 27, 2024
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Announces Pricing of $100.0 Million Public Offering of Common Stock
March 04, 2024
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Announces Proposed Public Offering of Common Stock
March 04, 2024
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update
February 28, 2024
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance to Release Fourth Quarter and Full Year 2023 Financial Results on Wednesday February 28, 2024
February 21, 2024
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance to Participate in Upcoming Investor Conferences
February 21, 2024
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Receives Permanent J-Code for DAXXIFY® and Announces Publication of DAXXIFY Pivotal Study (ASPEN-1) Results in Neurology®
February 02, 2024
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance to Participate in the Guggenheim 6th Annual Biotechnology Conference
February 01, 2024
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Provides Corporate Update, Preliminary Fourth Quarter and Full Year 2023 Financial Results, and Financial Outlook
January 08, 2024
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Reports Third Quarter 2023 Financial Results, Provides Corporate Update
November 08, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Appoints Erica Jordan as Chief Commercial Officer, Aesthetics
November 08, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance to Participate in Upcoming Investor Conferences
November 06, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance to Release Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
November 01, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
DAXXIFY® Becomes First Facial Injectable to be Named to TIME’s Best Inventions
October 26, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Provides Corporate Update at Investor Day
September 19, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance to Host Investor Day on September 19, 2023
August 22, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
U.S. FDA Approves First Therapeutic Indication for Revance’s DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia
August 14, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Reports Second Quarter 2023 Financial Results, Provides Corporate Update
August 08, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance to Release Second Quarter 2023 Financial Results on Tuesday, August 8, 2023
August 01, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance to Participate in Upcoming Investor Conferences
May 23, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Reports First Quarter 2023 Financial Results, Provides Corporate Update
May 09, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance to Release First Quarter 2023 Financial Results on Tuesday, May 9, 2023
May 02, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance to Participate in the Needham 22nd Annual Healthcare Conference
April 05, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Publishes its 2022 Environmental, Social, and Governance (ESG) Report
March 30, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance to Participate in Upcoming Investor Conferences
March 07, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
Wall Street Sees 23% Upside In Revance, Maker Of Botox Competitor
March 02, 2023
Revance Therapeutics gapped up 54.34% on January 9, and built upon those gains in February. The company reported its first revenue for Botox competitor Daxxify.
Via
MarketBeat
Revance Reports Fourth Quarter and Full Year 2022 Financial Results, Provides Corporate Update
February 28, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Adds Experienced Pharmaceutical Executive to Board of Directors with Appointment of Dr. Vlad Coric, M.D., as Independent Director
February 28, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance to Participate in the 43rd Annual Cowen Healthcare Conference
February 27, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance to Present New Data on DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia at the Association of Academic Physiatrists Annual Meeting
February 23, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.